Search alternatives:
significantly small » significantly smaller (Expand Search), significantly impact (Expand Search), significantly impair (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
small decrease » small increased (Expand Search)
significantly small » significantly smaller (Expand Search), significantly impact (Expand Search), significantly impair (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
small decrease » small increased (Expand Search)
-
1481
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1482
Multistimuli-Responsive Porous Organic Polymers for Drug-Gas Anticancer Combination Therapy
Published 2025Subjects: -
1483
-
1484
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1485
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1486
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1487
-
1488
-
1489
-
1490
-
1491
-
1492
-
1493
-
1494
-
1495
-
1496
-
1497
-
1498
-
1499
-
1500